Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.39 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059066 | 1.00 | SCN4A (0.39) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL16633513 | 0.90 | SCN4A (0.46) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL16633517 | 0.90 | SCN4A (0.46) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12920953 | 0.88 | CYP3A4 (0.38) | SCN4ATACR1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL26117817 | 0.81 | PRKCA (0.39) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30556088 | 0.81 | PRKCA (0.39) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15019827 | 0.80 | ALDH1A1 (0.36) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5727045 | 0.79 | CYP3A4 (0.36) | SCN4ACYP3A4HTTSMN1; SMN2 | |
| SCHEMBL23215033 | 0.78 | IDO1 (0.35) | SCN4ATACR1IDO1TDO2 | |
| SCHEMBL6124751 | 0.78 | IDO1 (0.35) | SCN4ATACR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | SCN4A 602/4885TACR1 453/4885CACNA1F 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.